Refractory Autoimmune Diseases clinical trials

Explore recruiting refractory autoimmune diseases clinical trials.

Recruiting refractory autoimmune diseases studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Refractory Autoimmune Diseases trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1 Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases

Germany, Romania, France, Spain, Czechia, Poland

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases (Breakfree-1)

Italy, France, Germany, Belgium, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

Refractory Autoimmune Diseases trials by city

Refractory Autoimmune Diseases clinical trials

Recruiting refractory autoimmune diseases studies right now

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis

A Clinical Study of CD19 CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases

US Zamto-cel Autoimmune Diseases

Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

Also recruiting in Europe

A Phase 1 Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases

A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases (Breakfree-1)

Refractory Autoimmune Diseases trials by city

Other conditions